Treatment with paroxetine, but not amitriptyline, lowers levels of lipoprotein(a) in patients with major depression.
High lipoprotein(a) (Lp(a)) levels constitute a major risk factor for vascular mortality. Major depression also increases the risk of cardiovascular disease. We measured the concentrations of Lp(a) in depressed patients and controls and studied the effects of antidepressant treatment and treatment outcome. Lp(a) levels were analysed at baseline in 35 in-patients with DSM-IV major depression who were then treated in a randomized double-blind manner with amitriptyline (n = 14) or paroxetine (n = 21), as well as in 33 healthy controls. Lp(a) levels were re-assessed after 4 weeks of treatment. We found a significant decrease in Lp(a) in patients treated with paroxetine, but not in those treated with amitriptyline. Our results suggest that antidepressant treatment with paroxetine might contribute to a decrease in vascular mortality risk irrespective of treatment outcome.
Central Institute of Mental Health, Mannheim, Germany. georgios.paslakis@zi-mannheim.de
Georgios
G
Paslakis
Daniel
D
Kopf
Sabine
S
Westphal
Maria
M
Gilles
Florian
F
Lederbogen
Bettina
B
Hamann
Isabella
I
Heuser
Michael
M
Deuschle
D000328:Adult; D000368:Aged; D000639:Amitriptyline / Q000627:therapeutic use*; D000928:Antidepressive Agents / Q000627:therapeutic use*; D003865:Major Depressive Disorder / Q000097:blood / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D017270:Lipoprotein(a) / Q000097:blood* / Q000502:physiology; D008297:Male; D008875:Middle Aged; D017374:Paroxetine / Q000627:therapeutic use*
D000928:Antidepressive Agents; D017270:Lipoprotein(a); D000639:Amitriptyline; D017374:Paroxetine